Endeavor Ireland’s Post

We're well on our way to securing our seed investment round for Kidney Beam and I am really excited to be presenting our investment opportunity an investor event hosted by Kidney Research UK on 5th March at 5pm. If you're interested in attending then I'd love to see you there. See below for how to RSVP... #seedfunding #impactinvesting #femalefounder #angelinvestment #kidneydisease #digitalhealth

Thanks to everyone that joined yesterday’s BPC x Cooley UK Biotech CEO event for a discussion on how to plan an exit strategy and navigate the preparations for cross over funding rounds and entering onto the public markets. We had three parts to the afternoons masterclass: ➡️An IPO bootcamp delivered by Courtney Tallman Thorne Partner at Cooley LLP the most active law firm representing biotechs listing in 2023 🔔🍾 ➡️ A panel discussion where we heard from the hands on experience of: Amit Shah from SR One Capital Management Dina Chaya from OrbiMed Elena Lovo, PhD from J.P. Morgan And Bobby Gaspar, CEO of Orchard Therapeutics ➡️ networking with a core group of biotech CEOs, investors, and industry experts 🧬🧪 My summary is that the experts believe we’re in for a much more upbeat year with as many as 36 biotech IPOs predicted for 2024 and that contenders are the companies that have compelling clinical data AND an investor base that can cover the book at least once over. For the others… it’s never too early to start planning! British Patient Capital Charlotte Davison Carmine Circelli Frances Stocks Allen Thomas Goodman

Brandon Capital, a leading life sciences VC firm in Australia, has another AUD $270 million (~ $180 million) to support 15 to 20 startups in drug development, health tech and medical devices. While the US-to-Europe life sciences investing axis is well established at this point, with many biotech VCs supporting new drug developers from Boston to Basel and elsewhere across the pond, the path between Australasia and Europe is less trodden, Brandon Capital partner Jonathan Tobin said in an interview with Endpoints News. #lifesciences #biotechfunding #biotechstartups #australia #australasia #venturecapital

🌟 Exciting news! After 15 months working with ILC Therapeutics as their fractional CFO, I’m thrilled to share that our recent fundraising round has been a success, and the cherry on top, my journey with the company continues 🚀. This round is a major milestone, helping us advance our two lead assets Alfacyte™ & Dermacyte™ towards clinic and hit key value inflection points for the business. 🎯 For those not in biotech, the closing of a fundraising round isn’t the time to slow down—it’s time to accelerate! 💥 and that's exactly what we are doing! I do have a sliver of capacity left (1-4 days/month) for fractional CFO work. If you or someone you know needs support, drop me a message! 📩 #FractionalCFO #FundraisingSuccess #Biotech #ClinicalTrials #Startups #CFO #BusinessGrowth #BiotechStartups #Leadership #Finance #Fundraising

Revolutionising Northern Ireland's Deeptech Landscape! In partnership with QUBIS Ltd, Queen's University Belfast, and Beauhurst, we proudly present the Northern Ireland Deeptech Index 2024. Highlights Include: 📌 £139M - A substantial total value of equity deals in IDEs created between 2017 - 2023, reflecting robust financial growth. 📌 QUBIS - As one of the Top 3 investors in IDEs, the commercialisation arm of Queen's University, Belfast contributes significantly to fostering innovation. 📌 82 - The number of active IDEs in Northern Ireland created between 2017 - 2023, indicative of a flourishing and dynamic ecosystem. 📌 ICURe Programme - Acknowledged as one of the premier deeptech accelerators in Northern Ireland, catalysing impactful advancements. This report deep dives into the vibrant landscape of Innovation-Driven Enterprises (IDEs) established in the last seven years. It highlights their pivotal role in spearheading innovation and contributing to the growth of the Northern Ireland economy. Read the full report here https://lnkd.in/e4NfhuDT and join the conversation on driving innovation in Northern Ireland. QUBIS Ltd Queen's University Belfast Beauhurst Brian McCaul Paul Donachy pHion Therapeutics Material Evolution Cloudsmith Sonrai Analytics VascVersa Ltd ANGOKA   #DeeptechInnovation #NIDeeptech #ICUReProgramme #IDEProgress

Of the 76 reasons we share with Mati Gill for being proud of Israel and the resilient people who call her home, number 68 might be our favorite: $3 billion in investments for the State of Israel! We never would have achieved this without you, our network of global investors. Together, we’re building a brilliant future. Read Mati Gill’s blog, “76 Reasons for Optimism,” on the Times of Israel: https://lnkd.in/eTZC2NQi Haven’t begun your investment journey yet? For as little as $36, you can start today. Learn more at israelbonds.com.

The Department of Industry, Science and Resources (DISR) has released another case study featuring PolyActiva, highlighting what can be achieved with support and investment into venture capital companies throughout the venture capital stages. ▶️ https://lnkd.in/g4kZHGnb PolyActiva is impressively pioneering an ocular implant for sustained drug delivery to the eye, which can deliver medication directly to affected tissue. If successful, this could be ground-breaking for glaucoma patients, many of whom are elderly and suffer sever impacts including blindness when forgetting to take medication or applying incorrect doses of it. PolyActiva’s ocular implant is inserted directly into the eye and the technology enables medication to be released as needed to the targeted area. The support and investment PolyActiva has received from Brandon Capital through the Australian Government's Biomedical Translation Fund, has enabled them to conduct the research and clinical trials to nurture innovation into commercially successful companies.   DISR is a partner of Innovation Bay’s VC community, Aurora, and is committed to fostering venture capital investment in startups. Explore some of the Australian Government’s diverse range of programs, including: 👉 Venture Capital Limited Partnerships https://bit.ly/3wzgo3r 👉 Early-Stage Venture Capital Limited Partnerships https://bit.ly/48vsHLu 👉 Australian Funds of Funds https://bit.ly/4bTK1wH 👉 Biomedical Translation Fund https://bit.ly/3uRZVa4 👉 Pooled Development Funds https://bit.ly/49AkPJR   These programs serve as catalysts for growth, facilitating globally competitive businesses. Noteworthy is the substantial impact of DISR's tax concession programs, attracting both foreign and local capital into the Australian venture capital sector. Since the inception of these initiatives, an impressive $30 billion in capital has been committed, benefiting approximately 2,500 early-stage businesses in scaling their ventures.   For those in the VC realm, we invite you to visit DISR's website to discover how their programs can elevate your investment strategies: https://bit.ly/3OjbMof https://bit.ly/3UlQUAE #DISR #VC #venturecapital #innovationbay #partner #departmentofindustryscienceresources #aurora #casestudy #business.gov.au #departmentofhealthandagedcare

After a productive networking break in the Great Room Foyer, we now have the “Medtech by the Numbers” Panel Session, moderated by Jennifer McMahon, Partner at Seroba.: • Inga D. Deakin, Principal, Molten Ventures • Megan MacDonagh, Vice President, SV Health Investors • Anne Portwich, Partner, EQT Life Sciences  • Sylvain Sachot, Partner, Asabys Partners 2023 life science investment went down across the board, in biotech and medtech equally, but in diagnostics and healthtech to a greater degree. A panel of European VCs discusses what’s in store for 2024. The number of up-rounds is down, which is a negative for VC firms supporting early-stage companies. The situation needs to change in order to reward early investment, the lifeblood of medtech innovation. We are seeing a lot of structured deals, option deals with many milestones. It does look good when a strategic is interested in a company, and it provides a path for exit. But it is a two-sided sword.   Remain informed on new articles, conference updates and more with our helpful medtech community newsletter. Subscribe here: https://bit.ly/42KHJKI

🌟 Exciting to see the conversation about bridging the equity gap in Europe gaining traction! At ScaleFund, we've been on a mission since 2017 to address precisely this issue. The statistics mentioned in this post reflect a critical challenge that we've been dedicated to overcoming. 💼 Our goal at ScaleFund has always been clear: to provide the necessary support and funding for promising scaleups to scale into successful, high-growth businesses. 🚀 Are you ready to join in bridging the equity gap and supporting the next generation of European scaleups? Let's make it happen! #ScaleFund #Scaleups #BridgingTheGap #Innovation #EuropeanScaleups

Recently, I had the privilege of attending an insightful update session led by the CEO of a cutting-edge medical company I invested in back in 2021. This company, specializing in groundbreaking cancer treatments and solutions for other diseases, has shown remarkable progress and innovation. During the session, not only did we witness a compelling demonstration of their advancements, but we also learned about the company's strategic move towards raising an additional 10 crores at a 100 crore valuation in a demerged entity. This pivotal moment has presented me, alongside fellow investors, with a golden opportunity to further invest at this increased valuation, courtesy of an offer extended by CEO to the investors. The dilemma that now stands before me is whether to seize this chance to augment my stake in a domain where genuine innovation is making waves or to diversify my portfolio by nurturing new ventures in their nascent stages. The growth from an initial valuation of 60 crores to a substantial 100 crores that too in the a part of the demerged company is not just numerical; it's a testament to the company's potential and the hard work behind it. After much contemplation, my inclination leans towards protecting and potentially increasing my share in the company. The rationale is straightforward: amidst the myriad of investments, only a select few demonstrate the capability to secure successive funding rounds. These are the true stars in a portfolio, promising not just returns but also contributing to significant advancements in their respective fields. As I ponder over this decision, I invite my network to share their insights and experiences. How do you approach such crossroads in investments? Do you prioritize the growth of your existing stakes in high-performing companies, or do you believe in the potential of diversifying by backing new entrants? Your perspectives could shed light on the multitude of strategies that seasoned investors employ, helping not just me but others in our community to navigate similar paths. #InvestmentDecisions #GrowthStrategy #MedicalInnovation #StartupInvesting #VentureCapital